China biopharmas forging western links to promote growth

22 June 2021

Chinese biopharma companies are eyeing strategic collaborations with western counterparts to leverage their extensive networks and commercial capabilities to promote indigenously developed drugs in China.

Data and analytics company GlobalData noted that China-based Luye Pharma Group’s holding subsidiary Boan Biotech signed an agreement with the Chinese unit of UK-based AstraZeneca (LSE: AZN) in May 2021 regarding the promotion rights to the anticancer drug Boyounuo (a biosimilar of Roche’s [ROG: SIX] Avastin [bevacizumab] injection), under which Boan will grant exclusive promotion rights to AstraZeneca across 21 provinces, municipalities, and autonomous regions of China.

Earlier this year, Shanghai-based Junshi Biosciences entered into exclusive agreement with AstraZeneca China for the promotion rights of toripalimab in mainland China for urothelial carcinoma.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK